(P062) SUVmax and Early Radiographic Changes as Prognosticators for Progression-Free Survival in Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy

Article

In patients with non–small-cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT), there are few established predictors of outcomes. Pretreatment maximum standardized uptake value (SUVmax) has recently been debated as a prognosticator of progression-free survival (PFS). Here, we present a retrospective series with up to 86 months follow-up evaluating potential prognosticators of outcomes.

Zachary D. Horne, MD, Paul P. Koffer, MD, Albert Yuen, MD, Michael L. Haas, MD; Reading Hospital Medical Center

Background: In patients with non–small-cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT), there are few established predictors of outcomes. Pretreatment maximum standardized uptake value (SUVmax) has recently been debated as a prognosticator of progression-free survival (PFS). Here, we present a retrospective series with up to 86 months follow-up evaluating potential prognosticators of outcomes.

Materials and Methods: Patients with primary stage I NSCLC (n = 80; median age 78 years; T1a = 33, T1b = 28, and T2a = 19) (American Joint Committee on Cancer [AJCC] 7th ed) were treated with SBRT between 2006 and 2013 at a regional medical center. All patients underwent motion studies to determine need for respiratory gating and were treated over a median of 9 days (range: 4–21 d). Survival curves were estimated using the Kaplan-Meier method, with the log-rank test and Cox proportional hazards regression utilized for univariate and multivariate analyses. Chi-square test and Pearson’s correlation were utilized to establish correlations between variables.

Results: The median follow-up was 21 months (range: 4.4–86.4 mo). Actuarial local (LC), regional (RC), and distant control (DC) at median follow-up was 96.3%, 92.5%, and 88.8%, respectively. Overall survival (OS) and progression-free survival (PFS) at median follow-up were 80% and 85%, respectively, with median OS of 43.5 months. Median PFS was not reached. Cancer-specific survival (CSS) at 2 and 5 years was 100% and 96.3%, respectively. Median time to initial follow-up CT scan was 1.8 months (range: 0.5–8.8 mo), with a median percent size reduction (PSR) of 22% (range: 36%–100%). On univariate Kaplan-Meier analysis, LC differed significantly by histology (P = .047). PFS was predicted to be worse by an SUVmax cutoff of 5.0 (P = .022) and, paradoxically, tumor reduction greater than the median percentage at first imaging (P = .025). As continuous variables, SUVmax and PSR at first follow-up remained significant for PFS on univariate Cox regression analysis (P = .008 and P = .049, respectively). Eleven percent of patients with < 22% tumor reduction progressed, while 36% of patients with > 22% tumor reduction progressed (P = .009), with the majority in the latter group being distant failures (P = .08). On multivariate analysis, SUVmax was the only significant predictor of improved PFS (P = .036), LC (P = .049), and DC (P = .032). SUVmax and PSR were found to be correlated by dichotomous comparison in two-sided chi-square (P = .026) and continuous comparison by one-tailed Pearson’s correlation (R = .224; P = .030).

Conclusions: SBRT is the standard of care in nonsurgical patients with early-stage NSCLC. Patients in this series with highly metabolic tumors experienced a greater degree of size reduction at first follow-up CT and appear to be at higher risk of progressive disease. Increased tumor reduction at first follow-up CT may serve as a trigger for closer observation or potential intervention. Higher pretreatment SUVmax may serve as a risk-stratifying variable in future studies evaluating the integration of systemic therapy with SBRT for early-stage NSCLC.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Tia DiTommaso, PhD, the senior director of preclinical pharmacology Arbor Biotechnologies, and John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
© 2025 MJH Life Sciences

All rights reserved.